A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology

• In-Seob Lee,
• Zhongxu Zhu,
• Jeeyun Lee,
• Joon Oh Park,
• Xiwei Wu,
• Tiffany Ong,
• Sierra Min Li,
• Xin Wang,
• Joseph Chao,
• Ajay Goel

Affiliations

In-Seob Lee

Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Comprehensive Cancer Center

Zhongxu Zhu

Department of Biomedical Sciences, City University of Hong Kong

Jeeyun Lee

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Joon Oh Park

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

Xiwei Wu

Integrative Genomics Core, Beckman Research Institute of City of Hope

Tiffany Ong

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center

Sierra Min Li

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center

Xin Wang

Department of Biomedical Sciences, City University of Hong Kong

Joseph Chao

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center

Ajay Goel

Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Comprehensive Cancer Center